Genecast Biotechnology, a Chinese biotech firm that specialises in next-generation sequencing (NGS) technology and bioinformatics, has secured over 1 billion yuan ($149 million) in a Series E round of financing, the firm announced on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in